Bliss GVS Pharma Notifies Shareholder of Unclaimed Dividend & Share Transfer to IEPF
Bliss GVS Pharma Limited is transferring unclaimed final dividends from 2018-2019 and corresponding shares to the IEPF Authority. This action complies with SEBI regulations and the Companies Act. The notice was published in newspapers on July 21, 2026.
This is a standard compliance procedure for unclaimed dividends and shares. It does not represent a new business development, financial result, or corporate action that would significantly impact the company's operations or stock price.
The announcement is a routine regulatory filing regarding the transfer of unclaimed dividends and shares to the IEPF, as mandated by law. It does not contain any information that positively or negatively impacts the company's financial performance or outlook.
Bliss GVS Pharma Limited has published a notice to its shareholders regarding the transfer of unclaimed final dividend for the financial year 2018-2019 and its corresponding equity shares to the Investor Education and Protection Fund (IEPF) Authority.
This action is in compliance with Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Section 124(6) of the Companies Act, 2013, read with the relevant IEPF rules.
The advertisement detailing this transfer was published in The Free Press Journal (English), Economic Times (English), Maharashtra Times, and Navshakti (Regional) on July 21, 2026. The notice is also available on the company's website at https://www.blissgvs.com/.
What to do with a filing like this
Bliss GVS Pharma Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bliss GVS Pharma Limited. Read the original for the full detail.